Page 3 - Real World Results News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article INDIANAPOLIS, April 23, 2021 /PRNewswire/  Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company s (NYSE: LLY) Taltz ® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PASI) 100. In three real-world analyses of U.S. claims data ranging from one to three years, patients treated with Taltz stayed on treatment longer, were more adherent to the prescription and had more days on monotherapy compared to the other biologics studied. These results are being presented virtually at the American Academy of Dermatology s Virtual Meeting Experience (AAD VMX), April 23-25, 20

United statesKevin hernMarkg lebwohlMarlo scottAndrew blauveltEli lillyExchange commissionAmerican academy of dermatology virtual meeting experienceOregon medical research centerIcahn school of medicine at mount sinaiPsoriasis area severity indexAmerican academyVirtual meeting experienceLotus mallbrisProvided patientsLongest lasting complete skin clearance